Remove 2009 Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

ACIP backs block on flu vaccines with thimerosal additive

pharmaphorum

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

UK follows through on doubling of statutory scheme rate

pharmaphorum

Skip to main content Wednesday 11 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

article thumbnail

15th World Clinical Biomarkers & Companion Diagnostics Summit | Free* for Biopharma

pharmaphorum

Skip to main content Friday 6 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Why pharma needs a revolution in culture

pharmaphorum

He was referring to his business’ share of misconduct related fines that, between 2009 and 2017, topped $342 billion across the US and Europe. It’s killing us.” As the sector looks to maintain its momentum, it must be wary that positive messaging and increased scrutiny does not end up as a recipe for a hard fall.

article thumbnail

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

pharmaphorum

She says she is “truly amazed” about what the industry has achieved in such a short time when it comes to innovations, vaccines and treatments. Camilla has a well-recognised track record working with various multinational companies, including AstraZeneca, Novartis and Allergan. About the author.

Hospitals 111
article thumbnail

Top 20 Radiopharma Companies Based on Market Cap

PharmaShots

The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients. Other radiotherapies under the company's pipeline include Humalutin and Alpha37. The company is evaluating Iomab-B in a P-III clinical trial (SIERRA) in patients with relapsed or refractory acute myeloid leukemia (AML).

FDA 56